Brand-name drug
Delestrogen price, strengths & recalls
Brand of estradiol (generic)
Pharmacies pay $127.52 for 5 mL of Delestrogen 10 mg/mL injection this week, and from $127.52 to $178.91 across its 2 priced strengths and forms. The generic, estradiol, costs pharmacies from $1.86. It has 253 recalls on record, none ongoing. Its official label last changed on May 20, 2026.
Brand- Fair cash price
- $157.15
- Strengths
- 2
- Makers
- 1
- Updated
- Nov 11
Delestrogen price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for the usual package. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 10 mg/mL injection Brand | $25.50 | $127.52 / 5 mL |
| 20 mg/mL injection Brand | $35.78 | $178.91 / 5 mL |
Delestrogen vs generic estradiol
Generics have the same active ingredient, strength and form, and FDA requires them to work the same way. What pharmacies pay for each, same quantity:
| Strength | Brand | Generic | Brand costs |
|---|---|---|---|
| 10 mg/mL injection | $127.52 | $91.84 | 1.4x |
| 20 mg/mL injection | $178.91 | $114.78 | 1.6x |
Supply status: shortages & recalls
Recalls
Showing the 6 most relevant of 253 - all recalls.
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Delestrogen
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
DELESTROGEN® (estradiol valerate injection, USP)
ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER
Close clinical surveillance of all women taking estrogens is important. Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal vaginal bleeding. There is no evidence that the use of "natural" estrogens results in a different endometrial risk profile than synthetic estrogens at equivalent estrogen doses [see WARNINGS, Malignant neoplasms, Endometrial cancer].
CARDIOVASCULAR AND OTHER RISKS
Estrogens and progestins should not be used for the prevention of cardiovascular disease [see WARNINGS, Cardiovascular disorders].
The Women's Health Initiative (WHI) study reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50 to 79 years of age) during 5 years of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone acetate (MPA 2.5 mg) relative to placebo [see CLINICAL PHARMACOLOGY, Clinical Studies].
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with oral conjugated estrogens plus medroxyprogesterone acetate relative to placebo. It is unknown whether this finding applies to younger postmenopausal women or to women taking estrogen alone therapy [see CLINICAL PHARMACOLOGY, Clinical Studies].
Other doses of oral conjugated estrogens with medroxyprogesterone acetate, and other combinations and dosage forms of estrogens and progestins were not studied in the WHI clinical trials and, in the absence of comparable data, these risks should be assumed to be similar. Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA009402 · Ph Health
- First approved
- July 15, 1954 (72 years ago)
- Latest approved change
- February 15, 2024
- Approved label
- PDF, Feb 20, 2024
- Generic makers
- 31 approved generic applications on the market
Delestrogen questions
How much does delestrogen cost without insurance?
Pharmacies pay about $127.52 for 5 mL of delestrogen 10 mg/mL injection ($25.50 per mL). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $157.15. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is there a generic for Delestrogen?
Yes: estradiol. Pharmacies pay from $1.86 for it. Compare estradiol prices.
Is delestrogen in shortage?
No shortage is reported for delestrogen right now. We check the national shortage list every day.
Has delestrogen been recalled?
253 recalls on record, none ongoing. Recalls name specific lots - check yours.
When did the delestrogen label last change?
The official label was last updated on May 20, 2026 (version 29). See what changed.
Talk about delestrogen
No comments yet. Questions, tips, what worked for you - start the conversation.